Acorda Therapeutics, Inc. (ACOR) said it is reducing headcount by 15%. The company estimates it will incur approximately $3.0 million of pre-tax charges for severance and other costs related to the restructuring, through the first quarter of 2022. Beginning in 2022, the company expects to realize annualized cost savings of approximately $20 million from the headcount reductions and the outsourcing of certain operations.
"The headcount reductions and structural changes will enable us to operate more efficiently and further align our expenses with revenue, while continuing to grow Inbrija sales," said Ron Cohen, Acorda's CEO.
Acorda Therapeutics also announced the appointment of Lauren Sabella, currently Chief Commercial Officer, as Chief Operating Officer. Kerry Clem, Executive Vice President of Sales, Market Access, and Operations, has been named Chief Commercial Officer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.